---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000070"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:24:54.407530+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma stockholders elect two Class I directors and approve potential Daewoong issuance at annual meeting

## Summary
- Robert Palmisano and Shelley Thunen elected as Class I directors for three-year terms ending 2027.
- Stockholders approved potential issuance of 20%+ of Class A common stock to Daewoong Pharmaceuticals at below-market value, a change-of-control measure.
- Ratification of KPMG LLP as auditor for fiscal 2024 passed with 25,491,112 votes for.
- All three proposals received sufficient votes; broker non-votes were 675,301 on first two proposals.

## SEC filing metadata
- accession: 0001837607-24-000070
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000070/0001837607-24-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000070/aeon-20240614x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000070
- JSON: https://secwatch.observer/filing/0001837607-24-000070.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.